BEVLiN: Prospective study of the safety and efficacy of first-line bevacizumab (BEV) plus low-dose interferon-α2a (IFN) in patients (pts) with metastatic renal cell carcinoma (mRCC).

Could Interferon Still Play a Role in Metastatic Renal Cell Carcinoma? A Randomized Study of Two Schedules of Sorafenib Plus Interferon-Alpha 2a (RAPSODY)

“…In addition, anti-VEGF agents other than sorafenib can be tested in combination with the frequent low-dose IFN regimen, thanks to their pharmacologic properties and therapeutic efficacy. The combination of bevacizumab with IFN has shown efficacy in the first-line treatment of mRCC [26,27], and this finding was confirmed when bevacizumab was combined with low-dose IFN [28]. Sunitinib has a superior potency compared with sorafenib, is associated with a high rate of CR [29], and the use of this drug in clinical practice is well-established [30].…”

Renal Cell Carcinoma Update: News from the AUA, EAU, and ASCO Annual Meetings 2011

“…At the last ASCO Annual Meeting, Melichar et al [ 36 ] presented an open-label, single-arm, prospective multinational phase II study (BEVLiN study) in which 147 nephrectomized MSKCC good- and intermediate-risk patients with clear cell RCC received bevacizumab combined with low-dose IFN α (3 MIU). This patient population was compared with an AVOREN subgroup ( n = 272) in which patients were treated with a higher IFN α dose (9 MIU).…”